| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Medical Devices | Ophthalmologic System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Medical Devices | Ophthalmologic System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Medical Devices | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Oculis Holding AG$13.63
-0.07 (-0.51%)
C 46Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.57 B
EPS
-2.28
P/E Ratio
-12.05 $
Value Trade
21.41 M
6.99 %
Week
39.78 %
1 Month
40.05 %
3 Month
60.06 %
6 Month
190.78 %
5 Year
190.78 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
201.54 K
52 Week Range
16 - 30.68
% held by Insiders
35.22 %
% held by Institutions
22.57 %
Enterprise Value
1.31 B
Total Shares
57.98 M
Short %
3.04 %
Float Shares
38.97 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Oculis Holding AG
303Total events
7Upcoming
55Tier-1 (high impact)
2022 – 2026Coverage
Upcoming catalysts 7
Event history 296
Jul 10, 2026
◆Oral PresentationPresentation
Oculis management to participate in fireside chat at Piper Sandler Virtual Ophthalmology Conference
Jun 13, 2026
◆Oral PresentationPrivosegtorPresentation
Presentation on Privosegtor in Optic Neuritis: From Discovery to PIONEER Registrational Trials at Clinical Trials at the Summit 2026
Optic Neuritissource ↗
Jun 9, 2026
◆Oral PresentationPresentation
Oculis management to present at 47th Annual Goldman Sachs Global Healthcare Conference
Jun 9, 2026
▲First Patient DosedlicaminlimabTrial
First patient randomized in PREDICT-1 registrational trial
Dry Eye Diseasesource ↗
Jun 2026
◆Topline ReadoutOCS-01Clinical Data
Topline results from Phase 3 DIAMOND program for OCS-01 in DME expected in June 2026
diabetic macular edemasource ↗
Jun 2026
◆Trial InitiationPrivosegtorTrial
PIONEER-3 trial initiation expected in mid-2026
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)source ↗
May 29, 2026
▼Topline ReadoutOCS-01Clinical Data
Topline results from Phase 3 DIAMOND-1 trial of OCS-01 in DME: primary endpoint not met
diabetic macular edemasource ↗
May 29, 2026
▼Primary Endpoint MissedOCS-01Clinical Data
DIAMOND trials failed to meet primary endpoint of mean change in BCVA at Week 52
diabetic macular edema (DME)source ↗
May 29, 2026
▼Program DiscontinuationOCS-01Corporate
Oculis will not pursue FDA approval for OCS-01 in DME based on DIAMOND results
diabetic macular edemasource ↗
May 29, 2026
●Oral PresentationPresentation
Oculis to hold analyst and investor call on May 29, 2026 at 4:30 PM ET to discuss DIAMOND results and pipeline
May 29, 2026
●Pipeline PrioritizationCorporate
Oculis to focus development on Privosegtor PIONEER program and Licaminlimab PREDICT-1 trial
May 13, 2026
Drug Pipeline Intelligence
C46
Pipeline Score $658M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.4x
rNPV / MCap Top 68%
Micro Cap (rank 293 of 911)
Percentile RankOculis Holding AG carries a moderate pipeline score (46/100), with $1.8B risk-adjusted pipeline value, led by Privosegtor in Optic Neuritis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Privosegtor Small molecule | Optic Neuritis | Phase 3 | NCT07623668 | 90% | $1.0B | RECRUITING | 210 | VERY_FAST | B (72) | Dec 1, 2028 | - | Jun 7, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Privosegtor BreakthroughPriorityOrphan | optic neuritis | Phase 2 | 2026-06-11 | Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina (GCIPL and RNFL layers) and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Read More | Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 Read More | |
Privosegtor BreakthroughPriorityOrphan | optic neuritis | Phase 2 | 2026-06-11 | Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina (GCIPL and RNFL layers) and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Read More | Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 Read More | |
Privosegtor BreakthroughPriorityOrphan | optic neuritis | Phase 2 | 2026-06-11 | Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina (GCIPL and RNFL layers) and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Read More | Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OCS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OCS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OCSOculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Oculis Holding AG will participate in the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The company plans to discuss its late-stage portfolio, including Privosegtor, a neuroprotective candidate with FDA Breakthrough Therapy designation, and Licaminlimab, a topical anti-TNFα for dry eye disease. The conference will also allow for one-on-one meetings with investors.
Read more →OCSOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis has published a notification regarding the purchase of ordinary shares by a member of its Executive Committee. This transaction reflects the company's commitment to transparency in managerial activities. The notification was made public on June 15, 2026, and is expected to bolster investor confidence.
Read more →OCSOculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
Oculis Holding AG will present its investigational drug Privosegtor at the Clinical Trials at the Summit 2026. The presentation will detail the drug's development as a potential neuroprotective therapy for optic neuritis, following positive Phase 2 trial results and regulatory designations. The event will take place in Las Vegas on June 12-13, 2026.
Read more →OCSOculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
Oculis has announced the randomization of the first patient in the PREDICT-1 trial, which is the first genotype-based registrational study for dry eye disease (DED). The trial aims to evaluate the efficacy of Licaminlimab, a precision medicine targeting the TNFR1 genotype. With a significant unmet need in DED treatment, Licaminlimab could offer a targeted solution for patients who currently face high discontinuation rates with existing therapies.
Read more →OCSOculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
Oculis Holding AG will participate in the 47th Annual Goldman Sachs Global Healthcare Conference, where management will discuss their late-stage portfolio. Key highlights include Privosegtor, a neuroprotective candidate with Breakthrough Therapy designation, and Licaminlimab, a topical anti-TNFα for dry eye disease. The company aims to address significant unmet medical needs in ophthalmology.
Read more →OCS▼ -15.3%on this news
Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating Oculis Holding AG for potential violations of federal securities laws following disappointing results from its Phase 3 DIAMOND trials. The trials failed to meet primary and secondary endpoints, and as a result, Oculis has decided not to pursue an FDA submission for its treatment OCS-01 for diabetic macular edema. Consequently, the company's stock experienced a significant decline. Investors who suffered losses are encouraged to join the investigation.
Read more →OCS▼ -36.1%on this news· ran to -48% by day 3shared move
Investor Relations LifeSci Advisors Corey Davis, Ph.D. cdavis@lifesciadvisors.com Media Relations ICR Healthcare Amber Fennell oculis@icrhealthcare.com Cautionary Statement Regarding Forward Looking Statements This press
Oculis recently announced the topline results from its Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema. Although the trials showed significant reduction in retinal thickness, the primary endpoints related to best corrected visual acuity were not met. As a result, the company has decided against pursuing an FDA filing for the drug in this indication. Oculis will instead focus on its ongoing PIONEER and PREDICT-1 programs while capitalizing on its strong financial position.
Read more →OCS▼ -23.4%on this news· ran to -56% by day 3shared move
Íslensk þýðing á fyrri tilkynningu; Oculis tilkynnir um helstu niðurstöður úr fasa 3 DIAMOND rannsóknunum á OCS-01 við sjónhimnubjúg af völdum sykursýki
Oculis announced disappointing results from its Phase 3 DIAMOND trials for OCS-01, which failed to meet the primary endpoint of improving visual acuity in patients with diabetic macular edema. Although a significant reduction in retinal thickness was observed, it did not translate into improved vision. The company will not pursue FDA approval for OCS-01 based on these results, but it maintains a strong financial position to support ongoing research.
Read more →OCS▼ -23.4%on this news· ran to -56% by day 3shared move
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
Oculis announced topline results from its Phase 3 DIAMOND trials of OCS-01 for diabetic macular edema. The primary endpoint of visual acuity improvement was not met, although a significant reduction in retinal thickness was observed. The company will now focus on other developmental programs and does not plan to pursue FDA filing for OCS-01 in this indication.
Read more →OCSOculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
Oculis Holding AG announced the results of its 2026 Annual General Meeting, where all agenda items were approved, including the election of Gregory D. Perry to the Board of Directors. The company reported a loss for 2025 and approved significant compensation packages for its board and executive members. Shareholders also endorsed a conditional share capital for employees and updated the Articles of Association.
Read more →OCSMs. Sylvia Cheung, CFO sylvia.cheung@oculis.com Investor Relations LifeSci Advisors Corey Davis, Ph.D. cdavis@lifesciadvisors.com Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous oculis@icrhealthca
Oculis Holding AG held its 2026 Annual General Meeting on May 13, 2026, where shareholders approved all agenda items, including the election of Gregory D. Perry to the Board of Directors. The company acknowledged a financial loss of CHF 33,670,000 for 2025, leading to an accumulated balance sheet loss of CHF 80,247,000. Compensation measures for executive members were outlined, indicating an approach to align rewards with performance. The meeting included amendments to the Articles of Association and the approval of treasury shares for future offerings.
Read more →OCSOculis Reports Q1 2026 Financial Results and Provides Company Update
Oculis Holding AG reported strong progress in its clinical pipeline during Q1 2026, highlighting key milestones for OCS-01 and Licaminlimab. The company is on track for significant data readouts in June and year-end, respectively. Additionally, Privosegtor's regulatory path has been cleared, enhancing its development prospects. The company maintains a robust cash position to support ongoing initiatives.
Read more →OCSOculis birtir uppgjör fyrir fyrsta ársfjórðung 2026 og kynnir áfanga í rekstri félagsins
Oculis Holding AG has reported its first-quarter financial results for 2026, highlighting significant progress in its clinical trials, particularly with OCS-01 and Licaminlimab. The company has secured a Special Protocol Assessment from the FDA for its PIONEER-1 study and has sufficient funds to support operations through 2029. Upcoming results from pivotal trials are expected in June 2026, which could lead to market approvals.
Read more →OCSOculis Holding AG Unaudited Condensed Consolidated Interim Financial Statements Table of Contents Unaudited Condensed Consolidated Interim: Statements of Financial Position as of
Oculis Holding AG has released its unaudited condensed consolidated interim financial statements for the period ending March 31, 2026. The report indicates a loss for the quarter of CHF 28,852, an improvement from the CHF 33,213 loss reported in the same quarter of the previous year. Notably, the company's cash and cash equivalents have decreased, amounting to CHF 64,564 at the end of the period. Increased research and development expenses pose challenges, prompting scrutiny of the company's financial health and operational efficiency.
Read more →OCS▲ +5.1%on this newsshared move
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
Oculis has secured a Special Protocol Assessment (SPA) agreement from the FDA for its PIONEER-1 trial, which evaluates Privosegtor for optic neuritis. This agreement confirms the trial's design and analysis are suitable for a future NDA submission. Privosegtor, a novel neuroprotective candidate, has shown promising results in prior trials and aims to address significant gaps in treatment for optic neuropathies.
Read more →OCSLatest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
The DME AWARE Delphi study findings were presented at the ARVO 2026 Annual Meeting, highlighting the need for non-invasive treatment options in diabetic macular edema (DME) management. Oculis is set to report topline results from the DIAMOND Phase 3 trials for OCS-01, a potential first-in-class eye drop therapy. The study emphasizes the importance of early intervention and the consensus among experts on improving patient care.
Read more →OCSOculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Oculis Holding AG will present key findings at the ARVO 2026 Annual Meeting, including results from the DME AWARE Delphi Study and a post-hoc analysis of the Phase 2 ACUITY trial for Privosegtor. The company aims to address unmet medical needs in diabetic macular edema and optic neuritis with its innovative therapies. CEO Riad Sherif will discuss the company's pipeline and milestones during the event.
Read more →OCSapproach to drive precision medicine in dry eye disease (DED); and Privosegtor, a breakthrough neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatme
Oculis Holding AG has announced its 2026 Annual General Meeting set for May 13, 2026, in Zug, Switzerland. The meeting will be held in-person, with no virtual option available. The company is focused on advancing its pipeline in neuro-ophthalmology, including OCS-01 for diabetic macular edema, Licaminlimab for dry eye disease, and Privosegtor, aimed at optic neuropathies. Shareholders can participate in an information session on May 11, 2026, to learn more about the meeting proposals.
Read more →OCSOculis Publishes Invitation to the Annual General Meeting
Oculis Holding AG has announced its 2026 Annual General Meeting scheduled for May 13, 2026, in Zug, Switzerland. The meeting will be held in-person and streamed, with specific arrangements for shareholders holding shares on different exchanges. An information session preceding the meeting will provide insights into the proposals and allow management to address shareholder questions. Oculis is focused on developing innovative treatments in neuro-ophthalmology and ophthalmology, emphasizing its advanced clinical pipeline.
Read more →OCSOculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
Oculis has completed the last patient visit in the Phase 3 DIAMOND program for OCS-01, an eye drop treatment for diabetic macular edema (DME). The trials involved over 800 patients and aimed to evaluate the efficacy and safety of OCS-01. Topline results are expected in June 2026, which could pave the way for a new non-invasive treatment option for DME, addressing significant unmet medical needs.
Read more →OCSOculis lýkur síðustu eftirfylgniheimsókn í fasa 3 DIAMOND rannsóknaráætluninni með OCS-01 augndropum til meðferðar á sjónhimnubjúg af völdum sykursýki
Oculis has completed the last follow-up visits for its Phase 3 DIAMOND trial of OCS-01, a non-invasive treatment for diabetic macular edema (DME). Over 800 patients participated in the trial, with results expected in June 2026. The company aims to position OCS-01 as the first topical treatment for DME, addressing unmet medical needs in the field.
Read more →OCSOculis to Participate in Upcoming Investor Conferences
Oculis Holding AG announced its participation in upcoming investor conferences in April 2026, where it will present updates on its late-stage clinical portfolio. The company is focused on addressing unmet medical needs in ophthalmology and neuro-ophthalmology. Key highlights include pivotal trial results for OCS-01 expected in June 2026 and the Breakthrough Therapy designation for Privosegtor.
Read more →OCS▲ +8.3%on this news
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Oculis has announced that its neuroprotective candidate, Privosegtor, has received PRIME designation from the European Medicines Agency for treating optic neuritis. This follows its recent Breakthrough Therapy designation from the FDA. The designation is supported by positive Phase 2 trial results, indicating significant vision improvements and neuroprotective benefits. Oculis is advancing its PIONEER program, which includes registrational trials for Privosegtor.
Read more →OCSOculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
Oculis Holding AG has announced the upcoming presentation of positive Phase 2 data for its investigational drug Privosegtor at the North American Neuro-Ophthalmology Society annual meeting. The trial results demonstrate significant improvements in low-contrast visual acuity and neuroprotective effects in patients with optic neuritis. As a Platinum Sponsor of the event, Oculis reaffirms its commitment to advancing neuro-ophthalmic therapies. The results support Oculis's future development programs, including the registrational PIONEER program for optic neuropathies.
Read more →OCSOculis Publishes 2025 Consolidated Financial Statements
Oculis has published its audited consolidated financial statements for the year 2025, along with the Management Discussion and Analysis (MD&A). These documents have been filed with the SEC using form 20-F. The announcement follows a previous press release on March 3, 2026. Additional attachments, including the financial statements and ESEF reporting, are included in the release.
Read more →OCSOculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
Oculis Holding AG reported strong financial results for Q4 and full year 2025, highlighting significant clinical advancements, particularly with Privosegtor, which received FDA Breakthrough Therapy designation. The company anticipates major milestones in 2026, including trial results for OCS-01 and Licaminlimab. Despite increased operating losses, Oculis's cash reserves have grown substantially, positioning it well for future developments.
Read more →OCSOculis Holding AG Consolidated Financial Statements Table of Contents Report of the statutory auditor to the General Meeting 2 Consolidated Statements of Financial Position as of
Oculis Holding AG's consolidated financial statements have been audited by PricewaterhouseCoopers SA, which found that the financial reports accurately represent the Group's position as of December 31, 2025. The audit complied with IFRS Accounting Standards and Swiss law, reflecting a rigorous approach to assessing the financial health of the company. Key audit matters included an examination of research and development expenses, which accounted for the majority of operational costs. The auditors confirmed their independence and adherence to ethical standards throughout the audit process.
Read more →OCSuncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject
Oculis has reported significant achievements in 2025, including advancements in their late-stage clinical portfolio and the granting of Breakthrough Therapy designation for Privosegtor in optic neuritis. The anticipated topline results from the DIAMOND Phase 3 trials with OCS-01 for diabetic macular edema are expected in Q2 2026. The company is well-positioned with a strong financial reserve of $268.7 million, supporting operations through 2029. However, they face challenges with an increasing net loss and rising operational costs.
Read more →OCSOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
Oculis has released notifications pertaining to transactions executed by individuals in managerial roles as well as those closely associated with them. The notifications primarily concern the vesting of earnout shares and the removal of restrictions on these ordinary shares. Specific transactions were noted for managers Anthony Rosenberg, Pall Johannesson, Riad Sherif, and Sylvia Cheung. This event highlights the company's ongoing management changes but does not convey notable positive or negative developments.
Read more →OCSOculis Appoints Katie Kazem as Chief Legal Officer
Oculis Holding AG has appointed Katie Kazem as Chief Legal Officer, effective immediately. Kazem brings over 15 years of experience in corporate and securities law, having previously served as external counsel to Oculis. The company is currently advancing its PIONEER program and preparing for pivotal Phase 3 results for its eye drop treatment, OCS-01, expected in Q2.
Read more →OCS▲ +5.1%on this news
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
Oculis has announced its plans to showcase its late-stage pipeline, which includes Privosegtor and OCS-01, at the 2026 J.P. Morgan Healthcare Conference. Privosegtor has received breakthrough therapy designation from the FDA for optic neuritis following positive Phase 2 trial results. The company is also advancing its OCS-01 eye drops for diabetic macular edema, with Phase 3 trial results expected in Q2 2026. This development indicates significant market potential with estimates exceeding $7 billion for optic neuropathies.
Read more →OCS▲ +5.8%on this news· ran to +17% by day 3shared move
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
Oculis Holding AG announced that its neuroprotective candidate, Privosegtor, received Breakthrough Therapy Designation from the FDA for treating optic neuritis. The designation follows promising results from the Phase 2 ACUITY trial, which demonstrated significant improvements in visual function. Privosegtor aims to become the first neuroprotective therapy for optic neuropathies, addressing a substantial market need.
Read more →OCSOculis birtir uppgjör fyrir þriðja ársfjórðung 2025 og kynnir áfanga í rekstri félagsins
Oculis Holding AG has released its financial results for the third quarter of 2025, highlighting significant progress in its drug development pipeline. The company is particularly focused on the upcoming Phase 3 trials for OCS-01, aimed at treating diabetic macular edema. Recent funding has bolstered its research efforts, although it reported a substantial net loss during the quarter due to increased operational costs. Oculis remains committed to addressing unmet medical needs in ophthalmology.
Read more →OCSOculis Reports Q3 2025 Financial Results and Provides Company Update
Oculis Holding AG reported its Q3 2025 financial results, highlighting significant advancements in its clinical pipeline, including OCS-01 eye drops in Phase 3 trials for diabetic macular edema and a new trial for Licaminlimab in dry eye disease. The company has secured substantial funding to support pivotal trials in optic neuropathies, with a strong cash position of nearly $300 million. Despite an increase in net loss, Oculis remains optimistic about its future developments and FDA interactions.
Read more →OCSOculis to Participate in Upcoming November Investor Conferences
Oculis Holding AG announced its participation in several investor conferences in November 2025, where it will present updates on its late-stage portfolio. Highlights include advancements in pivotal trials for its neuroprotective candidate Privosegtor and the diabetic macular edema treatment OCS-01. The company aims to establish itself as a leader in neuro-ophthalmology and ophthalmology.
Read more →OCS▼ -6.8%on this news
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
Oculis Holding AG has announced an oversubscribed financing round, raising $110 million through the sale of 5,432,098 ordinary shares priced at $20.25 each. The funds will be used to advance the development of Privosegtor, a neuroprotective candidate targeting acute optic neuritis and non-arteritic anterior ischemic optic neuropathy. The offerings are expected to close on November 3, 2025.
Read more →OCS▼ -6.8%on this newsshared move
Oculis greinir frá umframeftirspurn í 110 milljóna USD fjármögnun sem er ætlað til að hraða klínískri þróun Privosegtor
Oculis Holding AG has announced a successful public offering, raising $110 million to expedite the clinical development of its neuroprotective drug, Privosegtor, targeting acute optic neuritis and non-arteritic anterior ischemic optic neuropathy. The offering involved the sale of over 5.4 million shares at $20.25 each, with the proceeds aimed at enhancing clinical trials and general operational purposes. The company anticipates closing the offering around November 3, 2025.
Read more →OCSOculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
Oculis Holding AG will showcase its late-stage pipeline at Eyecelerator and the AAO Annual Meeting. Key updates include the advancement of Privosegtor into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy. The company will also present findings on OCS-01 eye drops for diabetic macular edema, with topline results expected in mid-2026.
Read more →OCS▲ +5.6%on this news· ran to +20% by day 3shared move
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy Successful meeting with FDA enables advancement into pivotal d
Oculis has announced the advancement of its candidate drug, Privosegtor, into registrational trials for acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION) following a successful meeting with the FDA. This marks a significant milestone, as Privosegtor has the potential to be the first neuroprotective therapy for these conditions, which currently lack effective treatments. The PIONEER program will include multiple global trials aimed at supporting the drug's registration, with the initial trials set to commence in late 2025 and early 2026. Oculis also has a strong financial position, with sufficient funds to support the ongoing development of Privosegtor.
Read more →OCSOculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities
Oculis has published a notification regarding transactions by a Person Discharging Managerial Responsibilities (PDMR) in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The notification pertains to trades executed under a trading plan by a PDMR, indicating standard compliance with regulatory requirements. This information is essential for investors monitoring insider trading activities.
Read more →OCS▲ +6.7%on this news
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
Oculis Holding AG announced the forthcoming presentation of positive results from the Phase 2 ACUITY trial investigating Privosegtor (OCS-05) for acute optic neuritis at ECTRIMS 2025. The trial demonstrated clinically meaningful improvements in vision and retinal structure preservation. The results highlight Privosegtor's potential for wider applications in treating neuro-ophthalmic and neurological diseases. The upcoming presentation will be led by Dr. Céline Louapre, showcasing these encouraging findings to the multiple sclerosis community.
Read more →OCSOculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
Oculis Holding AG, in partnership with EURETINA, has announced Dr. Prithvi Ramtohul as the winner of the Ramin Tadayoni Award 2025, recognizing his significant contributions to retinal research. The award honors postgraduate scholars in memory of the late Professor Ramin Tadayoni. Dr. Ramtohul aims to advance understanding of cellular mechanisms of amblyopia through his research. Oculis continues to support advancements in ophthalmic and neuro-ophthalmic fields with a robust pipeline of innovative treatments.
Read more →OCSOculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
Oculis Holding AG announced that it will present clinical trial results from its late-stage pipeline at upcoming ophthalmology conferences, including the EURETINA Congress. Notable presentations will include expanded data from the Phase 3 DIAMOND program for OCS-01 eye drops targeting diabetic macular edema and data from the Phase 2 ACUITY trial for Privosegtor (OCS-05) in acute optic neuritis. The company aims to demonstrate the therapeutic potential of these innovative treatments for significant unmet medical needs in ophthalmic diseases.
Read more →OCS▼ -5.6%on this newsshared move
Oculis to Participate in Upcoming September Investor Conferences
Oculis Holding AG, a biopharmaceutical company focusing on ophthalmic diseases, announced its participation in several investor conferences this September. CEO Riad Sherif and CFO Sylvia Cheung will attend events in Boston, New York, and Stockholm, engaging in presentations and discussions about the company's late-stage clinical pipeline. The events come as Oculis aims to attract interest and investment in its innovative treatment candidates for various eye and neurological conditions.
Read more →OCSOculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
Oculis has appointed Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors to enhance its leadership in neuro-ophthalmology and ophthalmology. This follows recent positive Phase 2 trial results for its drug Privosegtor (OCS-05) in acute optic neuritis and the completion of enrollment in Phase 3 trials for OCS-01 in diabetic macular edema. The appointments come at a critical time as Oculis aims to advance its innovative pipeline aimed at addressing significant unmet medical needs in ophthalmology. Both advisors bring extensive experience that is expected to significantly impact Oculis' development efforts and long-term strategy.
Read more →OCSOculis Reports Q2 2025 Financial Results and Provides Company Update
Oculis Holding AG reported its Q2 2025 financial results, highlighting advancements in its clinical pipeline for ophthalmology and neuro-ophthalmology. The pivotal Ph3 DIAMOND trials for OCS-01 have completed enrollment, with topline results expected in Q2 2026. Furthermore, the company is preparing to initiate a Phase 2/3 trial for Privosegtor based on encouraging results and expanding into new indications. Oculis maintains a solid financial position with significant cash reserves to support ongoing developments.
Read more →OCSOculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference
Oculis Holding AG, a biopharmaceutical company, will participate in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. CFO Sylvia Cheung will present a corporate update, while President of R&D Snehal Shah will join a panel discussion on pivotal stage assets for retinal disorders. The presentations and discussions will be accessible via a webcast posted on Oculis's website. This event underscores Oculis's commitment to addressing unmet medical needs in ophthalmic conditions.
Read more →OCSOculis Upsized Loan Facility to Access up to CHF 100 million
Oculis Holding AG has amended its loan agreement with BlackRock, increasing borrowing capacity from CHF 75 million to up to CHF 100 million. This enhanced financial flexibility aims to support key regulatory discussions and clinical trials, including three different indications of Privosegtor and Licaminlimab. The company is preparing for important milestones, with NDA filing expected in late 2026, contingent on trial results. Oculis maintains a strong cash position that offers runway into early 2028.
Read more →OCSMaximum value of equity-based compensation for three members of the Executive Committee until the end of the calendar year 2026: USD 15,500,000 (excluding employer social security and pension contributions). The sharehol
Oculis Holding AG held its 2025 Annual General Meeting on June 4, 2025, with shareholders approving all agenda items. Key resolutions included acceptance of the 2024 Financial Statements, acknowledging a loss of CHF 5,179,000 for 2024, and granting discharge to directors for their prior activities. Significant compensation amounts for executive members were approved, with a maximum equity-based compensation for three members reaching USD 15,500,000 until the end of 2026. The meeting also saw the re-election of board members and auditors.
Read more →OCSOculis Publishes Results of 2025 Annual General Meeting
Oculis Holding AG held its 2025 Annual General Meeting on June 4, 2025, in Zug, Switzerland, where shareholders approved all agenda items. Notably, the company reported a significant loss of CHF 5.18 million for 2024, carrying a total balance sheet loss of CHF 46.58 million forward. Despite this, shareholders re-elected key board members and confirmed substantial fixed and variable compensation for the executive team. Oculis continues to focus on innovative treatments for ophthalmic and neuro-ophthalmic diseases.
Read more →OCSOculis to Participate in Upcoming June Investor Conferences
Oculis Holding AG, a biopharmaceutical company specializing in ophthalmic diseases, announced its participation in two upcoming investor conferences: the Goldman Sachs Annual Healthcare Conference and the J.P. Morgan European Healthcare Conference. CEO Riad Sherif will host a fireside chat at the Goldman Sachs event, providing insights into the company’s innovative product pipeline. Oculis offers several candidates in development aimed at addressing significant unmet medical needs. One-on-one meetings for interested investors will also be available during the conferences.
Read more →OCSInvestor Relations LifeSci Advisors Corey Davis, Ph.D. cdavis@lifesciadvisors.com Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous oculis@icrhealthcare.com
Oculis Holding AG has published an invitation for its 2025 Annual General Meeting scheduled for June 4, 2025, in Zug, Switzerland. The meeting will be held in-person with an option for virtual attendance. Additionally, a virtual information session for shareholders will take place on May 19, 2025, to discuss proposals and answer questions. The company is engaged in developing innovative treatments for ophthalmic and neuro-ophthalmic diseases, highlighting its commitment to addressing significant unmet medical needs.
Read more →OCSOculis Reports Q1 2025 Financial Results and Provides Company Update
Oculis Holding AG reported positive developments for Q1 2025, showcasing advancements in its pipeline, including promising results from its Privosegtor (OCS-05) trial for acute optic neuritis. The company completed the enrollment of over 800 patients across two Phase 3 trials for OCS-01, with results expected in Q2 2026. Additionally, Oculis's cash position improved significantly due to recent financing, extending its operational runway into early 2028. However, despite these advancements, the company reported an increased net loss compared to the previous year, alongside rising R&D expenses associated with ongoing trials.
Read more →OCSOculis Reports Q1 Financial Results and Provides Company Update
Oculis Holding AG reported its Q1 financial results, highlighting major advancements across its key assets, including the positive ACUITY trial results for Privosegtor (OCS-05), which indicates significant neuroprotective effects. The company completed enrollment for two Phase 3 trials for OCS-01 targeting diabetic macular edema, with topline results expected by Q2 2026. Additionally, a personalized medicine approach with Licaminlimab (OCS-02) is set to initiate in the second half of 2025. Oculis's cash position is strong at $206.3 million, supporting their development plans into early 2028.
Read more →OCSOculis to Present at Upcoming May Investor Conferences
Oculis Holding AG has announced its participation in several upcoming investor conferences in May 2025, including events in Bruges, Las Vegas, New York, and a virtual forum. CEO Riad Sherif and CFO Sylvia Cheung are scheduled to deliver updates on the company's progress and innovative product pipeline. The company focuses on addressing unmet medical needs in ophthalmic and neuro-ophthalmic diseases, showcasing its commitment to research and development in this field. Interested investors will have opportunities for one-on-one meetings during these conferences.
Read more →OCSOculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
Oculis Holding AG announced its upcoming presentations of late-stage pipeline candidates at several major ophthalmology conferences, including the ARVO Annual Meeting and Retina World Congress. Key highlights include interim results from the DME AWARE Delphi Study and findings from the Phase 3 DIAMOND program for OCS-01 eye drops, which target diabetic macular edema (DME). Oculis also anticipates presenting positive results from the Phase 2b RELIEF trial for Licaminlimab (OCS-02) aimed at treating dry eye disease. These developments indicate a strong commitment to addressing significant unmet needs in ophthalmic conditions.
Read more →OCS▼ -5.8%on this news
Oculis Updates Share Capital
Oculis Holding AG has announced an increase in its registered share capital by issuing 589,974 ordinary shares, which include shares from equity award exercises and warrant executions. This raise takes the total number of registered shares to 54,533,674, as recorded with the Zug Commercial Register. The increase in shares may indicate positive investor sentiment and potential growth for the company.
Read more →OCSOculis and EURETINA Announce the 2025 Ramin Tadayoni Award
Oculis Holding AG, in collaboration with EURETINA, announced the 2025 Ramin Tadayoni Award, honoring the late Professor Tadayoni. The award, valued at €35,000, aims to support innovative research in retinal diseases and recognize exceptional postgraduate scholars. Applications are open until May 12, 2025, and will be awarded at the EURETINA Congress held in Paris in September 2025. The initiative reflects Oculis' commitment to scientific excellence and advancing the field of ophthalmology.
Read more →OCSOculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
Oculis Holding AG is hosting an R&D Day on April 15, 2025, to update stakeholders on its three late-stage clinical candidates, including OCS-01 for diabetic macular edema and Privosegtor for acute optic neuritis. The event will feature presentations from key opinion leaders and discuss recent clinical results and future development programs. Notably, the company anticipates topline data from the DIAMOND trials in Q2 2026. An investor meeting is scheduled in Iceland on April 29, further emphasizing Oculis's proactive communication strategy.
Read more →OCSOculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
Oculis Holding AG has successfully completed patient enrollment in its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01, a topical treatment for diabetic macular edema (DME). The trials have enrolled over 800 patients across 119 sites globally, with topline data anticipated in Q2 2026. If approved, OCS-01 would represent the first non-invasive topical therapy for DME, addressing significant unmet medical needs. The company plans to update stakeholders at its upcoming R&D Day.
Read more →OCSOculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
Oculis Holding AG has announced an upcoming in-person and virtual R&D Day set for April 15, 2025, to provide updates on its portfolio and ongoing clinical trials. The event will showcase advancements in therapies like OCS-01 for diabetic macular edema and Privosegtor for acute optic neuritis. Key opinion leaders will present recent clinical data and future directions of Oculis's development strategy. This meeting serves as a platform to highlight the company's commitment to addressing significant unmet medical needs in ophthalmic and neuro-ophthalmic diseases.
Read more →OCSOculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
Oculis has released notifications regarding stock transactions executed by a Person Discharging Managerial Responsibilities (PDMR), R. Sherif. These transactions occurred between March 14 and March 20, 2025, under a Rule 10b5-1 trading plan in compliance with the Securities Exchange Act of 1934. The notifications include multiple sales on consecutive days, highlighting ongoing insider trading activity. No specific insights on the company's performance or future prospects were disclosed.
Read more →OCSAbout Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS / XICE: OCS) purposefully driven to save sight and improve eye care. Oculis' highly differentiated pipeline of multiple innovative product candidates
Oculis reported its Q4 and full-year financial results for 2024, showcasing significant clinical progress in its pipeline targeting various ophthalmic conditions. The company achieved positive Phase 2 trial results for its treatments, Privosegtor (OCS-05) and Licaminlimab (OCS-02), and successfully completed a $100 million equity financing to support advancements in its clinical portfolio. Furthermore, Oculis highlighted its robust cash position expected to fund operations well into early 2028, despite an increase in net loss due to development costs. The upcoming R&D Day is slated for April 15, 2025, to discuss the company’s strategy and pipeline potential.
Read more →OCSOculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
Oculis Holding AG reported significant progress in its clinical pipeline for 2024, with positive results from its Privosegtor trial for acute optic neuritis and advancements in other treatments. The company completed a successful $100 million equity financing aimed at boosting its late-stage clinical portfolio. Despite these achievements, Oculis recorded an increased net loss in Q4 2024 compared to the previous year, influenced by rising clinical development expenses. Cash reserves are healthy, providing a runway into early 2028 and supporting upcoming trials.
Read more →OCS▲ +5.5%on this news
Oculis to Present at Upcoming March Investor Conference
Oculis Holding AG announced its participation in the Leerink Global Healthcare Conference on March 11, 2025, where CFO Sylvia Cheung will present. The company aims to engage with investors through one-on-one meetings and will provide a live webcast of the event. Oculis is recognized for its unique pipeline, including therapies for diabetic macular edema and dry eye disease. The company's operations span Switzerland, the U.S., and Iceland, supported by prominent healthcare investors.
Read more →OCSresults to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the c
Oculis Holding AG announced a successful pricing of an oversubscribed offering of 5 million ordinary shares at $20.00 per share, amounting to gross proceeds of $100 million. The offering is expected to close around February 18, 2025, subject to customary conditions. Proceeds will be directed towards advancing the clinical development of its neuroprotective candidate Privosegtor (OCS-05) as well as for working capital. The significant interest from investors underscores confidence in Oculis' pipeline and strategic direction.
Read more →OCSOculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
Oculis Holding AG has announced the pricing of an oversubscribed offering of 5,000,000 ordinary shares at $20 each, totaling $100 million in gross proceeds. The company intends to use the net proceeds to enhance its clinical pipeline, particularly for its neuroprotective candidate Privosegtor (OCS-05). The offering is set to close on or about February 18, 2025, pending customary conditions. This move underscores Oculis's strategy to expand its innovative product offerings in ophthalmic and neuro-ophthalmic diseases.
Read more →OCSOculis updates share capital for its existing at-the-market offering program
Oculis Holding AG has announced the issuance of 2,500,000 ordinary shares as part of its existing at-the-market offering program. This issuance will contribute to the company's treasury shares, which now represent 7.2% of its registered shares. Through an agreement with Leerink Partners LLC, Oculis may raise up to $100 million via future sales, although these new shares have not yet been sold. This move reflects the company's ongoing efforts to enhance its capital resources.
Read more →OCSOculis Publishes Notification of Major Changes in Voting Rights
Oculis has published a Notification of Major Changes in Voting Rights. This announcement details significant amendments related to the rights of shareholders in the company. Specific changes and their implications are expected to be outlined in the attached document, providing shareholders with key information moving forward.
Read more →OCSOculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective T
Oculis has reported positive topline results from the Phase 2 ACUITY trial for OCS-05, a potential neuroprotective therapy for acute optic neuritis. The trial met its primary safety endpoint and demonstrated statistically significant improvements in both retinal structure and visual function compared to placebo. This development positions OCS-05 as a leader in addressing an unmet need in neuroprotective treatment for optic nerve disorders. The successful trial results enable Oculis to initiate clinical development in the U.S., opening pathways for further advanced studies.
Read more →OCSSECURITIES AND EXCHANGE COMMISSION
On November 29, 2024, Oculis Holding AG submitted a report to the Securities and Exchange Commission concerning transactions by managerial personnel in compliance with EU Market Abuse Regulation. This notification complies with the filing requirements under the Securities Exchange Act of 1934. The report includes managerial transactions as detailed in Exhibit 99.1. Sylvia Cheung, Chief Financial Officer, signed the report.
Read more →OCS▲ +5.1%on this newsshared move
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities
Oculis has published a notification regarding a one-time equity incentive award granted to director Arshad Khanani. This award recognizes Khanani's independent consultancy services to the company. The transaction is part of the company's ongoing efforts to reward managerial contributions.
Read more →OCSOculis to Present at the Stifel 2024 Healthcare Conference
Oculis Holding AG (Nasdaq: OCS) announced its participation in the Stifel 2024 Healthcare Conference on November 18-19, 2024, where CFO Sylvia Cheung will speak during a fireside chat. The company plans to engage with investors and highlight its innovative pipeline, which includes treatments for diabetic macular edema and dry eye disease. Oculis aims to improve eye care and patient outcomes through its specialized therapeutic candidates. A live webcast of the discussion will be available for interested stakeholders.
Read more →OCSOculis Reports Q3 2024 Financial Results and Provides Company Updates
Oculis has reported its Q3 2024 financial results, highlighting substantial progress in its clinical pipeline, particularly with its OCS-01 and OCS-05 trials. The company has a robust cash position of $125 million, which is expected to sustain operations into the second half of 2026. Significant milestones include substantial patient enrollment in Phase 3 trials and a strengthened leadership team. However, the net loss for Q3 2024 has increased, primarily due to rising clinical development expenses, presenting potential financial risks as the company advances its pipeline.
Read more →OCS▲ +18.1%on this news
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
Oculis Holding AG has accelerated patient enrollment in its Phase 3 DIAMOND trials for OCS-01 eye drops aimed at treating diabetic macular edema (DME). As of early October 2024, approximately 70% and 40% of patients have been enrolled in the DIAMOND-1 and DIAMOND-2 trials, respectively. The trials are designed to evaluate the efficacy and safety of OCS-01, which, if approved, could be the first topical treatment for DME. The DIAMOND program committees have also expanded, adding prestigious retina experts to oversee the development process.
Read more →OCSOculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
Oculis Holding AG (Nasdaq: OCS) has announced that updates on its DIAMOND Phase 3 program for diabetic macular edema (DME) will be presented by its executives at Innovate Retina and Eyecelerator 2024. The presentations will highlight early positive results from Stage 1 of the trial for OCS-01, a topical dexamethasone eye drop formulation. Additionally, the design of Stage 2 will be discussed, which aims to evaluate the drug's efficacy and safety at Week 52. Oculis also anticipates unveiling topline results from the ACUITY Phase 2 trial for OCS-05, targeting acute optic neuritis, by the end of 2024.
Read more →OCSOculis Announces Appointment of Daniel S. Char as Chief Legal Officer
Oculis has announced the appointment of Daniel S. Char as its new Chief Legal Officer. Char, with over 35 years of experience in biotech legal leadership, will oversee Oculis' legal, compliance, and corporate governance functions. This appointment is aimed at strengthening the company as it progresses its late-stage pipeline and moves towards commercial phases, particularly with OCS-01, its first topical eye drop for retinal conditions. The CEO expressed confidence that Char's leadership will greatly benefit the company during this pivotal time.
Read more →OCSOculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
Oculis Holding AG, in collaboration with EURETINA, announced the winner of the inaugural Ramin Tadayoni Award, honoring the late Professor Tadayoni. Dr. Andrea Govetto received the award for his research on fluid flow and retinal tissue deformation in macular edema. The award acknowledges promising talent in retinal research, offering €30,000 for research support and €5,000 for the recipient. This announcement took place during the EURETINA congress in Barcelona, Spain.
Read more →OCSOculis to Present at Upcoming September Investor Conferences
Oculis Holding AG (Nasdaq: OCS) announced its management will attend and present at several upcoming investor conferences in September 2024, including events hosted by Wells Fargo and H.C. Wainwright. Oculis aims to enhance investor relations and highlight its innovative pipeline, which includes products targeting diabetic macular edema and dry eye disease. Interested investors are encouraged to contact their representatives for one-on-one meetings. The presentations will be accessible on the Oculis website.
Read more →OCSOculis Reports Q2 2024 Financial Results and Provides Recent Company Update
Oculis Holding AG reported its Q2 2024 financial results, highlighting major advancements in its clinical programs. The company announced positive topline results from the Phase 2b RELIEF trial of OCS-02, which may lead to the first precision medicine in Dry Eye Disease. Additionally, an NDA submission for OCS-01, aimed at post-operative inflammation treatment, is anticipated in Q1 2025. However, challenges were faced with the discontinuation of the Phase 3 OPTIMIZE-2 trial due to administrative issues.
Read more →OCSOculis Publishes Consolidated Q2 Financial Statements and MD&A
Oculis has published its Consolidated Q2 Financial Statements and Management Discussion and Analysis (MD&A). The announcement was made via a press release, and the documents have been filed with the SEC on form 6-K. This update provides stakeholders with insights into the company's financial performance for the second quarter.
Read more →OCSOculis Reports Q2 Financial Results and Provides Recent Company Update
Oculis Holding AG reported positive topline results from the Phase 2b RELIEF trial of OCS-02, which could lead to the first precision medicine for Dry Eye Disease. The company is also on track for the NDA submission of OCS-01 for treating post-operative inflammation in early 2025. Financially, Oculis holds $131.2 million in cash, ensuring operations into late 2026. However, the company reported increased net losses this quarter and will close the OPTIMIZE-2 trial due to administrative errors.
Read more →OCSOculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
Oculis Holding AG has appointed Dr. Sharon Klier as Chief Development Officer, enhancing its executive leadership team and U.S. presence. Dr. Klier brings over 20 years of experience in ophthalmology and drug development, particularly in securing FDA approvals. She will oversee clinical development efforts for Oculis' pipeline, which includes promising therapies for various eye diseases. The company is focused on delivering new treatments and improving patient outcomes.
Read more →OCS▼ -5.7%on this news
Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Oculis Holding AG (Nasdaq: OCS) will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, featuring CEO Riad Sherif in a panel discussion about late-stage candidates for retinal disorders. Additionally, Dr. Sherif will present a company presentation available on-demand. Oculis is focused on advancing its innovative pipeline, which includes several candidates targeting various eye conditions. This engagement highlights the company's commitment to improving eye care and saving sight.
Read more →OCSOculis and EURETINA Announces the Ramin Tadayoni Award
Oculis Holding AG announced the establishment of the Ramin Tadayoni Award in collaboration with EURETINA to honor the legacy of Prof. Ramin Tadayoni, its late Chief Scientific Officer. The award, offering €30,000 for research support and an additional €5,000 for the awardee, aims to recognize emerging talent in retina research. Applications will be accepted in June and July 2024, with the first award presented at the EURETINA Congress in September. This initiative highlights Oculis's commitment to advancing ophthalmic research and fostering new generations of ophthalmologists.
Read more →OCSOculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy Improvements in multiple sign effic
Oculis Holding AG announced positive topline results from its Phase 2b RELIEF trial of licaminlimab, a novel eye drop treatment for dry eye disease (DED). The trial demonstrated effectiveness across multiple pre-specified endpoints among 122 patients, suggesting a promising avenue for treatment in this common condition. The dual anti-inflammatory and anti-apoptotic mechanisms of licaminlimab further strengthen its potential to address unmet needs in DED management. Oculis plans to discuss these results with the FDA to outline future development steps for licaminlimab.
Read more →OCSstatements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forwar
Oculis Holding AG announced the results of its 2024 Annual General Meeting, where shareholders approved all agenda items including the election of new board members. Notably, Robert K. Warner and Arshad M. Khanani were elected to the Board, while Baruch D. Kuppermann and Frank G. Holz joined the Scientific Advisory Board. The Company also established a CHF 50 million loan facility with BlackRock to enhance financial flexibility. However, Oculis reported a financial loss of over CHF 41 million for 2023.
Read more →OCSOculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
Oculis Holding AG announced the outcomes of its 2024 Annual General Meeting, where shareholders approved all proposals including the election of new Board of Directors members Robert K. Warner and Arshad M. Khanani. The company also appointed Baruch D. Kuppermann and Frank G. Holz to its Scientific Advisory Board, aiming to leverage their expertise. Furthermore, Oculis secured a flexible loan facility of CHF 50 million while acknowledging a financial loss of CHF 41.4 million for the year ending 2023.
Read more →OCSOculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
Oculis Holding AG has announced the successful completion of patient enrollment in its Phase 2 ACUITY trial, which assesses the safety and tolerability of OCS-05 in individuals with Acute Optic Neuritis (AON). Topline results from the trial are expected in the fourth quarter of 2024. OCS-05 has been granted orphan drug designation in both the U.S. and Europe due to the lack of approved treatments for AON, an area of significant medical need. The completed enrollment serves as a crucial milestone as Oculis advances towards an Investigational New Drug application for OCS-05 in 2024.
Read more →OCSOculis Reports Q1 2024 Financial Results and Provides Company Updates
Oculis Holding AG reported its financial results for Q1 2024, highlighting successful progress in its clinical programs, including the initiation of a Phase 3 trial for OCS-01 in diabetic macular edema and completion of enrollment for the OCS-02 Phase 2b trial in dry eye disease. They successfully raised $59 million through a registered direct equity offering and enhanced their leadership team with key appointments. Despite a net loss of CHF 16.1 million for the quarter, the company's cash runway has been extended into the second half of 2026, allowing continued development of its pipeline.
Read more →OCSOculis to Present at Bank of America Global Healthcare Conference
Oculis Holding AG announced its participation in the Bank of America Global Healthcare Conference scheduled for May 14-16, 2024, in Las Vegas. CEO Riad Sherif will present on May 15. The company will also hold one-on-one meetings with interested investors during the conference. Oculis has a promising pipeline, including product candidates targeting conditions such as diabetic macular edema and dry eye disease.
Read more →OCSOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
Oculis announced the closing of a registered direct offering, raising gross proceeds of $59 million through the sale of ordinary shares. The company will commence trading on the Nasdaq Iceland Main Market on April 23, 2024, marking it as the second dual-listed company in both markets. This event will be celebrated by ringing the Nasdaq Iceland opening bell. The Phase 2b trial of OCS-02 in Dry Eye Disease is scheduled to provide results in the second quarter of 2024.
Read more →OCSAbout Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis' highly differentiated pipeline comprises multiple innovative product candidates in d
Oculis Holding AG (Nasdaq: OCS) has announced the successful closing of a registered direct offering, raising $59 million through the sale of 5 million ordinary shares. The company will begin trading on the Nasdaq Iceland Main Market under the symbol OCS on April 23, 2024, making it the second company to dual-list in both the U.S. and Iceland. Oculis is committed to innovative ophthalmology solutions, with its Phase 2b RELIEF trial of OCS-02 set to read out in Q2 2024.
Read more →OCSOculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
Oculis Holding AG has completed a $59 million oversubscribed registered direct offering and received approval to list its shares on the Nasdaq Iceland Main Market. The financing involves 5,000,000 shares sold at $11.75 each, with closing expected by April 22, 2024. Oculis aims to use the proceeds to further develop its clinical pipeline and support operations until mid-2026. The company emphasizes its commitment to innovative eye care solutions.
Read more →OCS▲ +6.2%on this newsshared move
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
Oculis Holding AG announced the appointment of Dr. Snehal Shah as President of Research & Development, aiming to strengthen its leadership team amid advancements in its late-stage pipeline. Dr. Shah joins from Iveric Bio, bringing over 20 years of experience in R&D and regulatory affairs in ophthalmology. His expertise is expected to facilitate future New Drug Application submissions to the U.S. FDA. Oculis continues to progress in clinical trials with promising candidates like OCS-01 and OCS-02, aiming to address significant unmet medical needs in ocular diseases.
Read more →OCSOculis to Participate at Upcoming April Investor Conferences
Oculis Holding AG (Nasdaq: OCS) announced its participation in upcoming investor conferences, including the Needham Annual Virtual Healthcare Conference and the Van Lanschot Kempen Life Sciences Conference in Amsterdam. CEO Riad Sherif will present at the Needham conference on April 11, 2024, with opportunities for one-on-one investor meetings. Oculis is focused on developing innovative treatments for various eye diseases, featuring several candidates in clinical stages, including OCS-01 and OCS-02, among others, aimed at addressing significant unmet medical needs.
Read more →OCSOculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
Oculis Holding AG reported strong financial results for Q4 and full year 2023, highlighted by a successful NASDAQ listing. The company achieved positive results in Phase 3 trials for its OCS-01 product targeting Diabetic Macular Edema and has initiated three additional clinical trials. With a solid cash position of $108.9 million, Oculis is well-positioned to advance its pipeline and expects key trial readouts in 2024. However, it faced significant net losses attributed to rising expenses from clinical development initiatives.
Read more →OCSOculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
Oculis Holding AG announced completion of enrollment for its Phase 2b RELIEF trial of Licaminlimab (OCS-02) in Dry Eye Disease, with topline results expected in Q2 2024. The company also initiated the second Phase 3 trial, DIAMOND-2, for OCS-01 targeting Diabetic Macular Edema. Additionally, Oculis appointed notable leaders, including Professor Ramin Tadayoni as Chief Scientific Officer and Virginia R. Dean as Chief Human Resources Officer, to strengthen its management team. The overall progress marks a positive momentum in Oculis' late-stage clinical development programs.
Read more →OCSOculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress • A successful year including NASDAQ listing and positive results from two Phase 3 programs in OCS-01: Phase 3 Stage 1 DIAMOND
Oculis Holding AG reported its fourth quarter and full year 2023 financial results, highlighting a successful NASDAQ listing and encouraging results from its Phase 3 OCS-01 trials for Diabetic Macular Edema and post-cataract surgery inflammation. The company is on track to report topline data from the Phase 2b RELIEF trial for Dry Eye Disease in Q2 2024, as well as continued advancements in its pipeline with multiple ongoing clinical trials. However, Oculis also noted a significant increase in net losses, attributed largely to clinical development expenses and a one-time merger cost. Overall, the company remains optimistic about its future milestones and funding, with a cash position poised to support operations through late 2025.
Read more →OCSOculis to Present at Upcoming February Investor Conferences
Oculis Holding AG announced its participation in two upcoming investor conferences in February 2024. The company will present its innovative eye care products, including its lead candidates OCS-01 and OCS-02, aimed at treating significant eye diseases. The events will provide opportunities for one-on-one meetings between the Oculis management team and interested investors. Oculis is focused on delivering advanced eye treatments globally and is led by an experienced management team.
Read more →OCSOculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
Oculis Holding AG will host an in-person and virtual R&D Day on February 28, 2024, in New York City, highlighting its clinical programs OCS-01 and OCS-02. OCS-01 is aimed at treating diabetic macular edema with a new eye drop formulation, while OCS-02 focuses on managing ocular inflammation in dry eye disease. The event will feature presentations from acclaimed medical professionals and a review of the company's business outlook for 2024. Attendees can engage in live Q&A sessions, emphasizing the commitment to advancing eye care innovations.
Read more →OCSOculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
Oculis has announced the commencement of the Phase 3 OPTIMIZE-2 trial for its eye drop candidate OCS-01, aimed at addressing inflammation and pain following cataract surgery. This initiative follows favorable results from the previous OPTIMIZE-1 trial, where OCS-01 demonstrated significant improvements in patient outcomes. The topline results from OPTIMIZE-2 are expected before the end of 2024 and will support a New Drug Application (NDA) submission to the FDA. Additionally, OCS-01 is being evaluated for other ocular conditions, reinforcing Oculis's commitment to advancing eye care treatments.
Read more →OCSOculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema
Oculis Holding AG has announced the initiation of Stage 2 in its Phase 3 DIAMOND-1 trial for the OCS-01 eye drops aimed at treating Diabetic Macular Edema (DME). The first patient visit was completed as planned, with Stage 1 showing significant efficacy and safety results. The trial aims to assess a non-invasive treatment approach for DME, which affects millions globally. If approved, OCS-01 could transform the management of this condition.
Read more →OCSOculis Reports Q3 2023 Financial Results and Provides Company Update
Oculis Holding AG reported positive advancements in its clinical programs during Q3 2023, particularly for its lead product OCS-01, which met key trial endpoints for inflammation and pain after cataract surgery. The company also initiated the LEOPARD trial for cystoid macular edema and reported a solid cash position of $116.5 million. However, Oculis faced financial challenges with a reported increase in net loss due to higher clinical development expenses. Looking forward, several pivotal trials are set to commence, with anticipated data readouts in 2024.
Read more →OCSOculis to Present at Upcoming November Investor Conferences
Oculis Holding AG (Nasdaq: OCS) has announced that its CEO, Riad Sherif, and CFO, Sylvia Cheung, will be presenting at several upcoming investor conferences in November. Events include the Stifel 2023 Healthcare Conference and the BTIG 3rd Annual Ophthalmology Day. The company aims to engage investors and provide updates on its innovative product pipeline, which addresses significant unmet needs in eye care. Oculis is committed to delivering life-changing treatments to patients globally.
Read more →OCS▼ -7.1%on this news
Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema
Oculis Holding AG announced it will present positive results from Stage 1 of its Phase 3 DIAMOND trial for OCS-01, a treatment for diabetic macular edema, at the 2023 American Academy of Ophthalmology Annual Meeting. The presentation is scheduled for November 3, 2023, in San Francisco. This trial's results are significant as OCS-01 aims to become the first non-invasive topical treatment for DME, addressing a critical need in eye care. The ongoing clinical trials suggest a promising future for Oculis's pipeline of innovative eye treatments.
Read more →OCSOculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema
Oculis Holding AG has announced the positive results from Stage 1 of its Phase 3 DIAMOND trial for OCS-01, an investigational treatment for diabetic macular edema (DME). The results will be shared as a late-breaking abstract at the 23rd EURETINA Congress in Amsterdam. OCS-01 aims to be the first topical, preservative-free eye drop for DME, differing from conventional invasive therapies. The company has a robust pipeline, including OCS-02 and OCS-05 in development for various eye diseases.
Read more →OCSOculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase
Oculis has appointed Rebecca Weil, Ph.D., as Chief Commercial Officer as it prepares for the pre-commercial phase of OCS-01, its lead product. The company has achieved positive results in late-stage trials for diabetic macular edema and inflammation post-cataract surgery, potentially positioning OCS-01 as a groundbreaking treatment. With Weil's extensive experience in ophthalmology and marketing, she will lead the commercial organization and strategies for Oculis's first US launch. The appointment aligns with Oculis's goal of delivering innovative eye care solutions to meet unmet medical needs globally.
Read more →OCSOculis Holding AG Unaudited Condensed Consolidated Interim Financial Statements Table of Contents Unaudited Condensed Consolidated Interim: Statements of Loss for the three and six months ended
Oculis Holding AG reported its unaudited condensed consolidated interim financial statements for the six months ending June 30, 2023. The company experienced a significant increase in operating losses, climbing to CHF 55,570, up from CHF 14,390 in the same period of the previous year. Comprehensive losses also rose sharply, totaling CHF 62,458, which includes high research and development expenses. Overall, the financial results reflect ongoing challenges within the company despite a slight increase in grant income and operating income.
Read more →OCSOculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update
Oculis Holding AG reported positive financial results for Q2 and the first half of 2023, highlighted by successful Phase 3 trial results for its lead product OCS-01 in treating diabetic macular edema and inflammation following cataract surgery. The company also raised approximately $146 million through its NASDAQ listing earlier this year. Despite the positive progress, Oculis reported a net loss of CHF 58.9 million for the first six months, driven by increased operating expenses from becoming a public entity. Looking forward, Oculis plans to advance its clinical programs and is optimistic about upcoming milestones in 2024.
Read more →OCSOCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery O
Oculis Holding AG announced positive results from the Phase 3 OPTIMIZE trial for its investigational eye drop, OCS-01, which treats inflammation and pain following cataract surgery. The study demonstrated that OCS-01 met both primary endpoints, showing significant efficacy with a once-daily dosing regimen. The treatment was well tolerated and had a favorable safety profile compared to the vehicle group. Given these results, OCS-01 could potentially become the first preservative-free corticosteroid eye drop regimen for post-ocular surgery care, significantly benefiting patients.
Read more →OCSOculis Announces to Present at Upcoming August Investor Conferences
Oculis Holding AG (Nasdaq: OCS) will present at several upcoming investor conferences, including the BTIG Virtual Biotechnology Conference and the Wedbush PacGrow Healthcare Conference. The company, based in Switzerland, is focused on developing innovative treatments for eye diseases with high unmet needs. Their pipeline includes candidates in various stages of clinical development for conditions like diabetic macular edema and dry eye disease. Oculis aims to provide life-changing eye treatments worldwide through these engagements with investors.
Read more →OCSOculis to Present at OIS Retina Innovation Summit
Oculis Holding AG (Nasdaq: OCS) announced that CEO Riad Sherif will participate in the OIS Retina Innovation Summit on July 27, 2023. Dr. Sherif will provide an update focusing on the positive Phase 3 Stage 1 readout of OCS-01 eye drops, aimed at treating Diabetic Macular Edema. The event will take place in Seattle, and a video recording of the presentation will be available afterward. Oculis continues to advance its pipeline of innovative treatments for various eye conditions.
Read more →OCSThese slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "p
Oculis conducted a research and development day, discussing multiple programs, including the OCS-01 Phase 3 DIAMOND Program targeting Diabetic Macular Edema. The presentation highlighted their forward-looking statements regarding clinical studies and regulatory strategies, acknowledging the inherent risks involved. Oculis also showcased the potential of their pipeline technologies such as TOPIREACH in treating retinal diseases and the development of ocular therapies. Overall, the R&D Day emphasized both the advancements made and the uncertainties that lie ahead for the company.
Read more →OCSOculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
Oculis Holding AG will host its inaugural R&D Retina Day on July 11, 2023, featuring discussions on its ongoing clinical programs targeting diabetic macular edema (DME), cystoid macular edema (CME), and acute optic neuritis (AON). Renowned retina specialists will present insights into the ongoing Phase 3 DIAMOND trial of OCS-01 and the proof-of-concept LEOPARD and ACUITY trials. Participants can attend in-person or virtually, and a Q&A session with experts will follow the presentations. Oculis aims to address significant unmet medical needs in eye care with its diverse clinical pipeline.
Read more →OCSOculis Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares ZUG, Switzerland and BOSTON, USA
Oculis Holding AG has announced the partial exercise of the underwriters' option to purchase additional ordinary shares, raising approximately $1.8 million. This follows the company's recent public offering which closed on June 5, 2023, totaling roughly $42.0 million in gross proceeds. Oculis is focused on developing innovative treatments for eye diseases and is currently progressing with multiple clinical trials. The company is headquartered in Switzerland and has operations in various global markets.
Read more →OCSOculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
Oculis has been awarded the 2023 Knowledge Award by the Icelandic Association of Business and Economics for its OPTIREACH formulation technology. This innovative technology enhances the delivery of topical eye drops to treat conditions like Diabetic Macular Edema, which is currently being assessed in Phase 3 clinical trials with the lead candidate OCS-01. Additionally, the award acknowledges Oculis' successful expansion of its portfolio with other clinical-stage candidates including OCS-02 and OCS-05. The recognition underscores the company's commitment to advancing eye care and improving patients' quality of life.
Read more →OCSOculis to Participate in Jefferies Healthcare Conference
Oculis Holding AG (Nasdaq: OCS) announced its participation in the 2023 Jefferies Global Healthcare Conference in New York, scheduled from June 7 to June 9. CEO Riad Sherif and CFO Sylvia Cheung will have 1:1 meetings and present on June 9. Oculis is advancing several clinical-stage product candidates for eye diseases with high unmet need, including OCS-01 for diabetic macular edema and OCS-05 for neuro-ophthalmic disorders. Their ongoing initiatives highlight their commitment to innovative eye care solutions.
Read more →OCSOculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares ZUG, Switzerland and BOSTON, USA
Oculis Holding AG announced the pricing of a follow-on public offering, aimed at raising approximately $40.25 million through the sale of 3,500,000 ordinary shares. The offering is expected to close around June 5, 2023, subject to typical closing conditions. The funds will be utilized to further its development programs targeting Diabetic Macular Edema and other ophthalmic conditions.
Read more →OCS▼ -7.8%on this newsshared move
Oculis Announces Launch of Proposed Public Offering of Ordinary Shares ZUG, Switzerland and BOSTON, USA
Oculis Holding AG announced a follow-on public offering of 5 million ordinary shares, with an option for underwriters to purchase an additional 15%. The funding from this offering will be directed towards its development programs, including treatments for Diabetic Macular Edema and other eye-related conditions. The offering is subject to market conditions and is intended to bolster Oculis's clinical-stage pipeline, which features multiple innovative product candidates. The registration statement related to this offering has been filed with the SEC but is not yet effective.
Read more →OCSOculis to Participate and Present at Upcoming EuDES Meeting
Oculis Holding AG (Nasdaq: OCS) will participate in the 2023 EuDES Meeting in Munich, Germany, presenting on the clinical efficacy of topical TNF alpha inhibitor OCS-02 for Dry Eye Disease. Dr. Bastian Dehmel, Oculis' Head of Development, is scheduled to deliver the presentation during a session focused on future developments in Dry Eye. Oculis, headquartered in Switzerland, is advancing several promising candidates in their clinical-stage pipeline aimed at addressing significant eye care needs.
Read more →OCS▲ +5.3%on this newsshared move
Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of
Oculis Holding AG announced positive top line results from Stage 1 of its Phase 3 DIAMOND trial for OCS-01 eye drops in Diabetic Macular Edema (DME). The trial showed a statistically significant improvement in visual acuity and a decrease in retinal thickness. Both primary and secondary endpoints were met, indicating potential for regulatory approval. The company plans to move forward with Stage 2 of the trial, which involves larger patient enrollments.
Read more →OCSOculis Co-founders Selected as Finalists in European Inventor Award 2023
Oculis co-founders, Professors Einar Stefánsson and Thorsteinn Loftsson, have been nominated as finalists in the 'Research' category of the European Inventor Award 2023 for their development of the OPTIREACH solubilizing formulation technology. This technology supports Oculis' lead candidate, OCS-01, which targets diabetic macular edema and addresses inflammation and pain following cataract surgery. The award ceremony will take place on July 4, 2023, in Valencia, Spain. Oculis continues to push the boundaries of ophthalmology with its innovative product pipeline.
Read more →OCSOculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs
Oculis has opened its new US headquarters in Boston, MA, as part of its expansion strategy following its NASDAQ listing. This move is accompanied by the appointment of Dr. Fang Li as Senior Vice President of Regulatory Affairs, who brings extensive experience in ophthalmology drug approvals. The Boston office will focus on supporting Oculis's upcoming clinical milestones, particularly concerning its OCS-01 product for treating diabetic macular edema and inflammation post-cataract surgery. This development reflects Oculis's commitment to becoming a significant player in the US market.
Read more →OCSRethinking Ophthalmology
Oculis is focusing on advancing ophthalmic innovations to address the significant unmet needs in eye care, particularly for conditions like Diabetic Macular Edema (DME) and Dry Eye Disease (DED). Their pipeline includes promising products such as OCS-01, targeting DME in Phase 3 trials, and OCS-02, a biologic eye-drop for DED in Phase 2b. The company emphasizes a strategic presence in key markets and early promising results can bolster their position as a leader in ophthalmology. Despite the positive outlook, challenges related to regulatory approvals and market dynamics remain.
Read more →OCSOculis to Participate at Upcoming Investor Conferences
Oculis Holding AG, a biopharmaceutical company focused on eye care, will participate in two upcoming investor conferences in April 2023. The conferences include the 22nd Annual Needham Virtual Healthcare Conference and the 16th Annual Kempen Life Sciences Conference, which will host investor meetings. The company aims to engage stakeholders by presenting its pipeline of product candidates, including treatments for serious eye conditions. Oculis is backed by an experienced management team and a robust investor base, emphasizing its commitment to advancing eye care solutions.
Read more →OCSOculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
Oculis Holding AG has announced plans to host a virtual conference call on April 13, 2023, to discuss its late-stage pipeline and upcoming clinical milestones. The call will provide insights into key product candidates like OCS-01 for diabetic macular edema and OCS-02 for dry eye disease. Management, along with notable ophthalmic experts, will address questions from participants during the session. This event marks a significant opportunity for stakeholders to gain clarity on Oculis's research and development directions.
Read more →OCS▼ -7%on this news
Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
Oculis Holding AG (Nasdaq: OCS) rings the Nasdaq opening bell to celebrate its recent public listing. The company focuses on advancing treatments for eye conditions and possesses a diverse pipeline including candidates for diabetic macular edema, dry eye disease, and acute optic neuritis. Notably, it has completed significant milestones in clinical trials with upcoming results expected. Support from prominent investors enhances its financial stability as it continues its mission to improve eye care.
Read more →OCSOculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial
Oculis Holding AG has completed enrollment in its Phase 3 OPTIMIZE trial for OCS-01, a topical, preservative-free corticosteroid aimed at treating inflammation and pain post-ocular surgery. The trial, which involves 240 patients at 25 sites across the US, assesses the drug's efficacy and safety. Previous studies have indicated that OCS-01 is effective and well tolerated, with hopes that it could simplify patient compliance due to once-daily dosing. If successful, OCS-01 may pave the way for newer treatment options in ocular care.
Read more →OCSOculis Announces US Public Listing on NASDAQ
Oculis has officially announced its listing on the Nasdaq under the ticker 'OCS' following a successful business combination with European Biotech Acquisition Corp. The deal, which has a pro-forma enterprise value of approximately $220 million and over $117 million in cash, was unanimously approved by shareholders. Oculis aims to advance its innovative clinical pipeline, including treatments for diabetic macular edema and dry eye diseases, with upcoming milestones expected to impact the ophthalmology field significantly.
Read more →OCSOculis Announces US Public Listing on NASDAQ Closing of business combination with European Biotech Acquisition Corp. creates Nasdaq- listed ophthalmology company, under the ticker OCS , with advanced clinical-stage pipel
Oculis Holding AG has successfully listed on Nasdaq following its business combination with European Biotech Acquisition Corp. The transaction was approved by both companies’ shareholders and valued Oculis at approximately $220 million. With this listing, Oculis intends to advance several innovative ophthalmology treatments, including topical candidates for diabetic macular edema and dry eye disease. The company is backed by significant institutional investors and aims to deliver life-changing therapies for various eye conditions.
Read more →OCSOculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with pr
Read more →OCSOculis establishes presence in U.S. and appoints Sylvia Cheung as Chief Financial Officer
LAUSANNE, Switzerland, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of patients, establishes its U.S. entity, Oculis Inc. and announces the strengtheni
Read more →OCSOculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer
LAUSANNE, Switzerland, March 03, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, today announced the appointment of Marcia de Souza Lima, M.D., M.I.P.P., as
Read more →OCSOculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone that has the potential to treat retinal diseases The Phase 2 (DX-211) study provides a clinical proof-of-concept of OCS-01 topical drug effect on DME The study met its pre-defined efficacy endpoints and s
Read more →OCSOculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in Patients with Diabetic Macular Edema (DME) at Angiogenesis, Exudation, and Degeneration 2020
LAUSANNE, Switzerland, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, today announced that a presentation on Phase 2 data from its investigational
Read more →OCSOculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone also in a Phase 2b trial for diabetic macular edema (DME) LAUSANNE, Switzerland, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel
Read more →OCSOculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Board
-- Eric D. Donnenfeld, M.D., internationally recognized expert and pioneer in refractive, cornea and cataract surgery -- Ramin Tadayoni, M.D., Ph.D., renowned professor and ophthalmologist in the diagnosis and treatment of retinal diseases, retinovitreal surgery and ophthalmic i
Read more →Competitive Position
How OCS ranks across every disease it competes inCompetitive Position is a premium feature
See how OCS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial